This live session took place on March 26, 2019

Led by expert analysts from Decision Resource Group’s Global Market Access Insights team, this webinar examines key events from 2018 that are shaping the future of global market access. This informative session explores critical questions including:

  • What similar themes are affecting different geographies around the world?
  • What trends are expected to have the greatest impact in 2019?
  • Where are the opportunities and concerns as countries wrestle with treatment payment?
  • What evolving trends are certain to affect the market access landscape into the next decade?


Roy Moore, Principal Director, Global Market Access Insights : 

Roy Moore oversees DRG’s Global Market Access team, including content for Access & Reimbursement and the Global Market Access Solution (GMAS).

Yulia Privolnev, Manager, Global Market Access Insights :

Yulia Privolnev works on DRG’s EU Access & Reimbursement and Global Market Access Solution (GMAS) product lines. She focuses on all aspects of market access in Western and Eastern Europe, as well managed entry agreements (MEAs) and international reference pricing (IRP) globally.

Steve Edgar, Senior Manager, Global Access :

Steve Edgar leads an internal team of analysts focused on evaluating business questions surrounding pharmaceutical market access for DRG’s Global Market Access Solution (GMAS).

Yazan Saleh, Analyst, Global Access Insights :

Yazan Saleh is responsible for monitoring the evolving healthcare and pharmaceutical landscapes with a focus on Canada, China, Japan, Saudi Arabia, and South Africa. He is primarily involved in analyzing and reporting on the impending regulatory and market changes that impact access to these regions through DRG’s Global Market Access Solution (GMAS) platform.

Special Guest Expert:

Akash Saini, PhD., Lead Analyst – Infectious, Niche and Rare Diseases :

Akash Saini, Ph.D., is a Lead Analyst with the Infectious, Niche, and Rare Diseases team at Decision Resources Group, where he specializes in a diverse group of rare diseases. He received his Ph.D. in biochemistry and biotechnology from the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India and his M.Sc. in biotechnology from Jawaharlal Nehru University, New Delhi, India.

Mainland China’s anticipated biosimilar boom – potential and key drivers of the market

View Now